You are here

Inflammatory Bowel Diseases - 10th Congress of ECCO, Barcelona, February 18-21, 2015

  • T. Billiet

    • Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary non-response to infliximab in Crohn’s disease patients
    • Closing remarks and take home message
  • M. Julsgaard

    • Adalimumab and infliximab levels in neonates - ERA Study
    • Conclusions - Adalimumab and infliximab levels in neonates - ERA Study
    • Closing remarks and take home message
  • J. Axelrad

    • Patients with inflammatory Bowel Disease and a history of cancer: the risk of cancer following exposure to immunosuppression
    • Closing remarks and take home message
  • I. Haaf

    • EFCCA European Federation of Crohn’s & Ulcerative Colitis Associations
    • The project of EFCCA
    • Associations play an important role
    • Patients have to face many challenges
    • Closing remarks and take home message
  • F. Carbonnel

    • Methotrexate for corticosteroid-dependent ulceritive colitis: results of a place randomized controlled trial
    • Methotrexate - an old drug which offers many advantages
    • Closing remarks and take home message
  • D. Laharie

    • Long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with cyclosporine or infliximab
    • Closing remarks and take home message
  • C. Hawkey

    • Prolonged deep remission of Ileocolonic Crohn’s disease following autologous haemopoetic stem cell transplantation, presented on behalf of all the ASTIC Trialists
    • Closing remarks and take home message